Acceleron Pharma Inc (XLRN)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Habib J. Dable
Employees:
173
128 SIDNEY STREET, CAMBRIDGE, MA 02139
617-649-9200

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Acceleron Pharma, Inc. is a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.

Data derived from most recent annual or quarterly report
Market Cap 10.886 Billion Shares Outstanding60.901 Million Avg 30-day Volume 1.285 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-1.16
Price to Revenue93.0026 Debt to Equity0.0166 EBITDA-253.48 Million
Price to Book Value14.6031 Operating Margin-226.57080000000002 Enterprise Value9.847 Billion
Current Ratio12.142 EPS Growth-0.77 Quick Ratio10.89
1 Yr BETA 0.5647 52-week High/Low 189.99 / 108.82 Profit Margin-226.0068
Operating Cash Flow Growth-140.9975 Altman Z-Score88.4114 Free Cash Flow to Firm -248.652 Million
View SEC Filings from XLRN instead.

View recent insider trading info

Funds Holding XLRN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding XLRN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MCLAUGHLIN KEVIN F SVP, CFO AND TREASURER

  • Officer
0 2021-11-19 2

KEARNEY TERRENCE C

  • Director
0 2021-11-19 1

ZAKRZEWSKI JOSEPH S

  • Director
0 2021-11-19 1

KANGO SUJAY EVP, CHIEF COMMERCIAL OFFICER

  • Officer
0 2021-11-19 3

NADER FRANCOIS

  • Director
0 2021-11-19 1

MCCOURT THOMAS A

  • Director
0 2021-11-19 1

SMITH KAREN L.

  • Director
0 2021-11-19 1

DABLE HABIB J CEO AND PRESIDENT

  • Officer
  • Director
0 2021-11-19 2

HAMILL LAURA

  • Director
0 2021-11-19 1

VENESS ADAM M SVP, GENERAL COUNSEL AND SEC.

  • Officer
0 2021-11-19 5

BACKSTROM JAY T. EVP, RESEARCH AND DEVELOPMENT

  • Officer
0 2021-11-19 1

MALIK KEMAL

  • Director
0 2021-11-19 1

HITE CHRISTOPHER

  • Director
0 2021-11-19 1

CELGENE CORP /DE/

BRISTOL MYERS SQUIBB CO

  • 10% Owner
No longer subject to file 2020-07-09 0

GEORGE JEAN

  • Director
5,127 2020-01-22 0

QUISEL JOHN D EVP, CHIEF BUSINESS OFFICER

  • Officer
53,316 2020-01-02 0

BRISTOL MYERS SQUIBB CO

  • 10% Owner
6,971,772 2019-11-20 0

KUMAR RAVINDRA SVP & CHIEF SCIENTIFIC OFFICER

  • Officer
86,986 2019-09-10 0

POPS RICHARD F

  • Director
32,500 2019-01-25 0

MANIATIS TOM

  • Director
136,731 2019-01-25 0

ZELDIN ROBERT K EVP & CHIEF MEDICAL OFFICER

  • Officer
19,103 2019-01-25 0

CELGENE CORP /DE/

6,824,685 2019-01-18 0

SHERMAN MATTHEW L EVP & CHIEF MEDICAL OFFICER

  • Officer
77,267 2018-04-03 0

ROVALDI CHRISTOPHER SVP, PROGRAM MGMT AND OPS

  • Officer
25,858 2018-04-03 0

MCGUIRE TERRANCE

  • Director
1,250 2017-03-02 0

ERTEL STEVEN D EVP & CHIEF OPERATING OFFICER

  • Officer
136,977 2017-03-02 0

KNOPF JOHN L CEO AND PRESIDENT

  • Officer
  • Director
214,084 2016-11-09 0

KANIA EDWIN M JR

  • Director
0 2015-01-08 0

MCGUIRE TERRANCE

POLARIS VENTURE MANAGEMENT CO IV LLC

POLARIS VENTURE PARTNERS ENTREPRENEURS FUND IV LP

POLARIS VENTURE PARTNERS IV LP

  • Director
  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
2,621,738 2014-06-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ACCELERON PHARMA INC XLRN 2021-11-22 22:15:03 UTC -0.3154 0.3854 250000
ACCELERON PHARMA INC XLRN 2021-11-22 21:45:03 UTC -0.3154 0.3854 250000
ACCELERON PHARMA INC XLRN 2021-11-22 21:15:03 UTC -0.3154 0.3854 250000
ACCELERON PHARMA INC XLRN 2021-11-22 20:45:03 UTC -0.18 0.25 250000
ACCELERON PHARMA INC XLRN 2021-11-22 20:15:03 UTC -0.18 0.25 250000
ACCELERON PHARMA INC XLRN 2021-11-22 19:45:03 UTC -0.18 0.25 250000
ACCELERON PHARMA INC XLRN 2021-11-22 19:15:03 UTC -0.18 0.25 250000
ACCELERON PHARMA INC XLRN 2021-11-22 18:45:03 UTC -0.18 0.25 250000
ACCELERON PHARMA INC XLRN 2021-11-22 18:15:03 UTC -0.18 0.25 250000
ACCELERON PHARMA INC XLRN 2021-11-22 17:45:03 UTC -0.18 0.25 250000
ACCELERON PHARMA INC XLRN 2021-11-22 17:15:03 UTC -0.18 0.25 250000
ACCELERON PHARMA INC XLRN 2021-11-22 16:45:04 UTC -0.18 0.25 250000
ACCELERON PHARMA INC XLRN 2021-11-22 16:15:03 UTC -0.18 0.25 250000
ACCELERON PHARMA INC XLRN 2021-11-22 15:45:03 UTC -0.18 0.25 250000
ACCELERON PHARMA INC XLRN 2021-11-22 15:15:03 UTC -0.18 0.25 250000
ACCELERON PHARMA INC XLRN 2021-11-22 14:45:03 UTC -0.18 0.25 250000
ACCELERON PHARMA INC XLRN 2021-11-22 14:15:03 UTC -0.18 0.25 250000
ACCELERON PHARMA INC XLRN 2021-11-22 13:45:03 UTC -0.18 0.25 250000
ACCELERON PHARMA INC XLRN 2021-11-22 13:15:03 UTC -0.18 0.25 250000
ACCELERON PHARMA INC XLRN 2021-11-22 12:45:03 UTC -0.18 0.25 250000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Defensive Long Fund XLRN -6.0 shares, $-539.22 2020-03-31 N-PORT
FundVantage Trust- Gotham Master Neutral Fund XLRN -28.0 shares, $-3150.84 2020-09-30 N-PORT
JNL Series Trust- JNL/AQR Large Cap Relaxed Constraint Equity Fund XLRN -2546.0 shares, $-345263.06 2021-03-31 N-PORT
Nuveen Investment Trust- Nuveen Equity Market Neutral Fund XLRN -1500.0 shares, $-196335.0 2021-05-31 N-PORT

Elevate your investments